netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand.  
Chapter Links...
 Details...
08.01  Expand sub section  Cytotoxic drugs
08.01  Expand sub section  Side-effects of cytotoxic drugs
08.01  Expand sub section  Drugs for cytotoxic-induced side-effects
Calcium Folinate
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Green
  • Calcium Folinate Tablets
  • Calcium Folinate Injection
  • Calcium Folinate Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Disodium Folinate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Disodium Folinate Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Mesna
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Mesna Injection
  • Mesna Tablets
  • Mesna Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    08.01.01  Expand sub section  Alkylating drugs
    Cytotoxic Drug Bendamustine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Bendamustine Injection

    Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Bendamustine is also available for other indications funded by the CDF

     
    Link  Cancer Drug Fund - Bendamustine
    Link  NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011)
    Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
     
    Cytotoxic Drug Chlorambucil
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Chlorambucil Tablets

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Cyclophosphamide
    (Chemotherapy)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Cyclophosphamide Suspension
  • Cyclophosphamide injection
  • Cyclophosphamide Tablets
  • Cyclophosphamide Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Melphalan
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Melphalan Tablets 


    Restricted for use within agreed protocols under the supervision of appropriate specialists

     
     
    08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics to top
    Cytotoxic Drug Bleomycin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Bleomycin Injection
  • Bleomycin Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Doxorubicin Hydrochloride
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Doxorubicin Injection
    • Liposomal doxorubicin Injection
       
     
    Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
     
    Cytotoxic Drug Epirubicin hydrochloride
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Epirubicin Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Mitomycin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Mitomycin Injection
  • Mitomycin C Injection
  • Mitomycin C bladder instillation

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Pixantrone intravenous infusion (Pixuvri® )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Pixantrone Intravenous Infusion

    Restricted for use as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas in-line with NICE TA306.  
  • Link  NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma (February 2014)
     
    08.01.03  Expand sub section  Antimetabolites
    Cytotoxic Drug Azacitidine (Vidaza®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Azacitidine Injection

     Supported for use in line with NICE TA218.

     
    Link  NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011)
     
    Cytotoxic Drug Capecitabine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Capecitabine Tablets
       
     
    Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006)
    Link  NICE TA191: Capecitabine for the treatment of advanced gastric cancer (July 2010)
     
    Cytotoxic Drug Cladribine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Cladribine Injection (LITAK® for subcutaneous injection)
       


    Restricted for use within agreed protocols under the supervision of appropriate specialists

     
    Link  MHRA Drug Safety Update: Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected (December 2017)
     
    Cytotoxic Drug Cytarabine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Cytarabine Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Fludarabine Phosphate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Fludarabine Tablets
       
      Supported for use in line with NICE TA116 and TA29.
     
    Link  NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007)
    Link  NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (September 2001)
     
    Cytotoxic Drug Fluorouracil
    (Chemotherapy)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Fluorouracil Injection
  • Fluorouracil Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Gemcitabine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Gemcitabine Injection
       
     
    Link  NICE TA116: Gemcitabine for the treatment of metastatic breast cancer (January 2007)
    Link  NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer (May 2001)
    Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
     
    Cytotoxic Drug Mercaptopurine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber SCG
  • Mercaptopurine Tablets

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  • Link  Mercaptopurine and Azathioprine Shared Care Guideline for Inflammatory Bowel Disease
     
    Cytotoxic Drug Methotrexate
    (Chemotherapy)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Methotrexate Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  • Link  DSU: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing (September 2020)
    Link  EMA: EMA reviewing risk of dosing errors with methotrexate (April 2018)
    Link  SPS Q&A: Should patients drink alcohol whilst taking long-term low-dose methotrexate? (December 2018)
     
    Cytotoxic Drug Pemetrexed
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Pemetrexed Injection
       


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)
    Link  NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (September 2009)
    Link  NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer (August 2017)
    Link  NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016)
     
    Cytotoxic Drug Trifluridine-tipiricil (Lonsurf®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Trifluridine Tipiricil Tablets (Lonsurf®) 


     
    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer (August 2016)
     
    08.01.04  Expand sub section  Vinca alkaloids and etoposide
    Cytotoxic Drug Etoposide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Etoposide Capsules
  • Etoposide Injection
  • Etoposide Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Vinblastine Sulphate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Vinblastine Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Vincristine Sulphate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Vincristine Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Vinorelbine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Vinorelbine Injection (reserved for patients unable to swallow capsules)
    • Vinorelbine Capsules

      Restricted for use within agreed protocols under the supervision of appropriate specialists
     
     
    08.01.05  Expand sub section  Other antineoplastic drugs
    Atezolizumab infusion
    View adult BNF View SPC online View SMC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Atezolizumab infusion

     

    Consultant Oncologist use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017)
    Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018)
    Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018)
    Link  NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019)
    Link  NICE TA638:Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (July 2020)
    Link  NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (July 2020)
     
    Cytotoxic Drug Axitinib (Inlyta®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red

     Patients who require treatment of renal cell carcinoma should be referred to Leeds Teaching Hospital Trust

    Axitinib is not stocked at Airedale NHS Foundation Trust

     
    Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015)
     
    Brentuximab infusion (Adcetris®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Brentuximab infusion

    For treatment of CD30-positive cutaneous T-cell lymphoma in-line after at least one other therapy (second-line) with NICE TA577. 

    Consultant Haematologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017)
    Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017)
    Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018)
    Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019)
    Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (August 2020)
     
    Cytotoxic Drug Crizotinib (Xalkori®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Crizotinib Capsules (Xalkori®)
       


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  MHRA Drug Safety Update: Crizotinib - risk of cardiac failure (November 2015)
    Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
    Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
    Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018)
     
    Daratumumab infusion  ( Darzalex®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Daratumumab infusion (Darzalex®)

    Consultant Haematologist use only. 

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  DSU: Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus (August 2019)
    Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018)
    Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019)
     
    Dasatinib (Sprycel®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    High Cost Medicine
    Cancer Drugs Fund
    BlueTeq
    • Dasatinib Tablets

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
     
    Durvalumab
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Durvalumab Infusion

    Supported for treatment of locally advanced non small-cell lung cancer after platinum-based chemo radiation in-line with NICE TA578.

    Consultant oncologist use only.

     
    Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019)
     
    Cytotoxic Drug Eribulin  ( Halaven®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Eribulin Solution for Injection


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016)
    Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018)
     
    Cytotoxic Drug Ibrutinib (Imbruvica®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Ibrutinib capsules

    Consultant Haematologist use only

    Ibrutinib is only available via the CDF. For further information see the link below.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  Cancer Drugs Fund
    Link  Drug Safety Update:Ibrutinib: reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017)
    Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017)
    Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017)
    Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
     
    Isatuximab infusion (Sarclisa®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Isatuximab infusion®

    For the treatment of relapsed and refractory myeloma (with pomalidomide and dexamethasone) under MHRA Early Access to medicines Scheme. 

    Consultant Haematologist use only.

     

     
     
    Cytotoxic Drug Neratinib  (Nerlynx®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Niraparib tablets (Nerlynx®)

    Approved as an option for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab in-line with provisional NICE recommendations.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
     
    Cytotoxic Drug Niraparib (Zejula®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Niraparib Capsules (Zejula®)


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

    Consultant Oncologist use only

     
    Link  TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018)
     
    Nivolumab (Opdivo®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Nivolumab Infusion

    Consultant Oncologist use only.

    For use at Specialist Centres only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  DSU: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019)
    Link  MHRA Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
    Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017)
    Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017)
    Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017)
    Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017)
    Link  NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018)
    Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019)
    Link  TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (May 2019)
     
    Cytotoxic Drug Olaparib  (Lynparza®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    • Olaparib capsules - For the treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer in-line with NICE TA381.

     

    • Olaparib tablets - For maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in-line with NICE TA598.

      Consultant Medical Oncologist use only 
     
    Link  DSU: Olaparib: Risk of medication errors with new pharmaceutical form (May 2018)
    Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
    Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (August 2019)
    Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (January 2020)
    Link  SSC2101 - Olaparib 2nd and 3rd line treatment of ovarian, fallopian tube or peritoneal cancer (December 2019)
     
    Cytotoxic Drug Pembrolizumab (Keytruda®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq

    For use at specialist centres only in line with NICE TA357 and TA366.

    For treating for treating PD-L1-positive non-small-cell lung cancer after chemotherapy in-line with NICE TA428 and NICE TA447.

    For locally advanced or metastatic urothelial cancer after platinum-containing therapy in-line with NICE TA519

    Consultant Medical Oncologist use only

     

    Approved for Hodgkin lymphoma in-line with NICE TA540

    Consultant haematologist use only

     

    Approved for first-line treatment (in combination with pemetrexed and cisplatin chemotherapy) of metastatic, non-squamous non-small-cell lung cancer in patients with no EGFR or ALK-positive mutations with NICE TA557.

    Consultant Oncologist use only

     

    Approved for use (in combination with carboplatin and paclitaxel) as an option for untreated metastatic squamous NSCLC in-line with NICE TA600 

    Consultant Medical Oncologist use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
    Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
    Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017)
    Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018)
    Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018)
    Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018)
    Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018)
    Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only]
    Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019)
    Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (September 2019)
    Link  NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (September 2020)
    Link  NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
     
    Pertuzumab  (Perjeta®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    High Cost Medicine
    Cancer Drugs Fund
    BlueTeq
    • Pertuzumab Infusion

    Pertuzumab is also available for some indications via the CDF. For further information see the link below.  

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Cancer Drug Fund
    Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016)
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
    Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019)
     
    Cytotoxic Drug Ponatinib (Iclusig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Ponatinib tablets

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Drug Safety Update: Ponatinib (Iclusig): risk of vascular occlusive events—updated advice on possible dose reduction (April 2017)
    Link  DSU: Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome (October 2018)
    Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017)
     
    Cytotoxic Drug Ribociclib (Kisqali®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Ribociclib tablets (Kisqali®)

    Approved by D&TC as a treatment option (with fulvestrant) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in-line with NICE TA593

     

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
     
    Cytotoxic Drug Rucaparib tablets (Rubraca®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Rucaparib tablets
       

    Consultant Oncologist use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019)
     
    Venetoclax
    View adult BNF View SPC online View SMC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Venetoclax film-coated tablets 

    Consultant Haemotologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017)
    Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019)
     
    08.01.05  Expand sub section  Amsacrine
    08.01.05  Expand sub section  Arsenic trioxide to top
    08.01.05  Expand sub section  Bevacizumab
    Cytotoxic Drug Bevacizumab (Avastin®)
    (Oncology)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Bevacizumab Infusion

    Bevacizumab is only available for via the CDF. For further information see the link below.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Cancer Drug Fund: Bevacizumab
    Link  MHRA Drug Safety Update:Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)
    Link  NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend]
    Link  NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend]
     
    08.01.05  Expand sub section  Bexarotene
    08.01.05  Expand sub section  Bortezomib
    Cytotoxic Drug Bortezomib (Velcade®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Bortezomib Injection

    Bortezomib is also available for some indications via the CDF list. See link below for further information.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Cancer Drugs Fund
    Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007)
    Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)
    Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015)
     
    Cytotoxic Drug Carfilzomib (Kyprolis®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Carfilzomib infusion

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  DSU: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events (August 2019)
    Link  DSU: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus (November 2019)
    Link  NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017)
     
    Cytotoxic Drug Ixazomib (Ninralo®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Ixazomib capsules

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
     
    08.01.05  Expand sub section  Cetuximab
    Cytotoxic Drug Cetuximab (Erbitux®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Cetuximab Infusion

    Available via NHSE. See the link below for further information.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED
    Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only)
    Link  NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED
    Link  NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
    Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017)
    Link  TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
     
    08.01.05  Expand sub section  Crisantaspase to top
    08.01.05  Expand sub section  Dacarbazine and Temozolomide
    Cytotoxic Drug Dacarbazine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Dacarbazine Injection
  • Dacarbazine Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    08.01.05  Expand sub section  Hydroxycarbamide
    Cytotoxic Drug Hydroxycarbamide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Hydroxycarbamide Capsules

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    08.01.05  Expand sub section  Ipilimumab
    08.01.05  Expand sub section  Mitotane
    08.01.05  Expand sub section  Panitumumab to top
    Cytotoxic Drug Panitumumab infusion (Vectibix®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Panitumumab infusion (Vectibix®) 

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
     
    08.01.05  Expand sub section  Pentostatin
    08.01.05  Expand sub section  Platinum compounds
    Cytotoxic Drug Carboplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Carboplatin Injection
  • Carboplatin Infusion

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Cisplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Cisplatin Infusion
  • Cisplatin Injection

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    Cytotoxic Drug Oxaliplatin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Oxaliplatin Injection
       
     
    Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006)
    Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)
     
    08.01.05  Expand sub section  Porfimer sodium and temoporfin
    08.01.05  Expand sub section  Procarbazine
    Cytotoxic Drug Procarbazine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Procarbazine Capsules

    Restricted for use within agreed protocols under the supervision of appropriate specialists 
  •  
    08.01.05  Expand sub section  Protein kinase inhibitors to top
    Abemaciclib tablets  (Verzenios® )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Abemaciclib tablets (Verzenios®)

    Consultant Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
    Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
    Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
     
    Cytotoxic Drug Afatinib (Giotrif®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Afatinib Tablets (Giotrif®)


     
    Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
     
    Cytotoxic Drug Alectinib capsules  (Alecensa®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Alectinib Capsules (Alecensa®)

    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
     
    Cytotoxic Drug Bosutinib (Bosulif®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Bosutinib Tablets

      Consultant Haematologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation(May 2016)
    Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
     
    Cytotoxic Drug Brigatinib tablets (Alunbrig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Brigatinib tablets (Alunbrig®)

    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
     
    Cytotoxic Drug Ceritinib capsules  (Zykadia®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Ceritinib Capsules (Zykadia®)


    Consultant Medical Oncologist use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
    Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
     
    Cytotoxic Drug Dacomitinib (Vizimpro®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Dacomitinib Tablets

     

    Consultant Oncology use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019)
     
    Cytotoxic Drug Erlotinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Erlotinib Tablets


     
    Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
    Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
    Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
     
    Cytotoxic Drug Everolimus (Afinitor®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Everolimus Tablets (Afinitor®)

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
    Link  NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
    Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
    Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
     
    Cytotoxic Drug Gefitinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Gefitinib Tablets

     
    Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
    Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
     
    Cytotoxic Drug Idelalisib (Zydelig®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Idelalisib Tablets


     
    Link  EMA recommends new safety measures for Zydelig (March 2016)
    Link  MHRA Drug Safety Update: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection (September 2016)
    Link  NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
    Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019)
     
    Cytotoxic Drug Imatinib
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Imatinib Tablets


     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
    Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
    Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
    Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
     
    Cytotoxic Drug Larotrectinib 20mg/mL oral solution  (Vitrakvi®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Larotrectinib 20mg/mL oral solution (Vitrakvi®)

      Consultant Medical Oncologist use only.

      Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)
     
    Cytotoxic Drug Lorlatinib (Lorviqua®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    NHS England
    BlueTeq
    • Lorlatinib Tablets (Lorviqua®)

             Consultant Medical Oncologist use only.

          Blueteq® registration and approval for use is required for this product before it may be        dispensed.

     
    Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)
     
    Cytotoxic Drug Nilotinib (Tasigna®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Nilotinib Tablets

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
    Link  NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
     
    Cytotoxic Drug Nintedanib capsules  (Vargatef®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Nintedanib Capsules (Vargatef®)


     
    Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
    Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
     
    Cytotoxic Drug Osimertinib mesylate ( Tagrisso®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    BlueTeq
    • Osimertinib Tablets

    Consultant Medical Oncologist use only.

     

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
     
    Cytotoxic Drug Palbociclib (Ibrance®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Palbociclib capsules
    • Palbociclib capsules with fulvestrant injection


    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
    Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020)
     
    Cytotoxic Drug Ribociclib (Kiskali®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Ribociclib Tablets

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
    Link  TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019)
     
    Cytotoxic Drug Ruxolitinib (Jakavi®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    • Ruxolitinib Tablets


     
    Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
     
    08.01.05  Expand sub section  Taxanes
    Cytotoxic Drug Cabazitaxel (Jevtana®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Cabazitaxel Concentrate for Infusion

      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016)
     
    Cytotoxic Drug Docetaxel
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Docetaxel Injection


     
    Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)
    Link  NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
     
    Cytotoxic Drug Paclitaxel
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Paclitaxel Injection
    • Paclitaxel Infusion
    • Paclitaxel as albumin-bound nanoparticles Infusion
       
     
    Link  NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
    Link  NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015)
    Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
    Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003)
     
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    Cytotoxic Drug Irinotecan Hydrochloride
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Irinotecan Injection
       
     
    Link  DSU: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events (March 2019)
    Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
    Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017)
     
    Cytotoxic Drug Topotecan
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Topotecan Injection 
       
     
    Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
    Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
    Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
    Link  NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)
     
    08.01.05  Expand sub section  Trabectedin
    08.01.05  Expand sub section  Trastuzumab
    Cytotoxic Drug Trastuzumab (Herceptin® Ontruzant®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Trastuzumab Intravenous Injection (Herceptin®)
    • Trastuzumab Subcutaneous Injection (Herceptin ®)
       
     
    Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)
    Link  NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)
    Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)
     
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Trastuzumab emtansine Powder for Concentrate for Solution for Infusion (Kadcyla®
       
     
    Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017)
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
    Link  NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (June 2020)
     
    08.01.05  Expand sub section  Tretinoin to top
    08.02  Expand sub section  Drugs affecting the immune response
    08.02  Expand sub section  Immunosuppressant therapy
    08.02.01  Expand sub section  Antiproliferative immunosuppressants
    Azathioprine
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary Amber Traffic Light  Azathioprine Tablets
    Red Traffic Light  Azathioprine injection 
    Link  Azathioprine and Mercaptopurine Gastroenterology Shared Care Guideline
    Link  Azathioprine Rheumatology Shared Care Guideline
    Link  Link to Leeds Share Care Guideline: Adult liver transplant
    Link  Link to Leeds Shared Care Guideline: Adult renal transplant
     
    Mycophenolate Mofetil
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber SCG
    • Mycophenolate Mofetil Capsules
    • Mycophenolate mofetil 1gram/5ml suspension

      Prophylaxis of acute renal, cardiac or hepatic transplant rejection (in combination with ciclsporin and corticosteroids) under specialist supervision

      Also supported for use by consultants for the following specialties (unlicensed uses):

      1. Rheumatology - Usually considered in active SLE or other serious connective tissue diseases and vasculitides
      2. Gastroenterology – considered in very occasional inflammatory bowel disease patients and autoimmune hepatitis
      3. Neurology – usually considered in myasthenia gravis as steroid sparing agent.
      4. Respiratory
      a. idiopathic pulmonary fibrosis intolerant to azathioprine often awaiting lung transplant
      b. pulmonary vasculitides (Wegner’s granulomatosis, CSS and microscopic polyangitis)
     
    Link  DSU: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018)
    Link  MHRA Drug Safety Update: Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis (January 2015)
    Link  MHRA Drug Safety Update: Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men (December 2015)
    Link  Mycophenolate mofetil Shared Care Guideline
    Link  NICE TA85 - Immunosuppressive therapy for renal transplantation in adults (September 2004)
     
    08.02.02  Expand sub section  Corticosteroids and other immunosuppressants
    Ciclosporin
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber SCG
  • Ciclosporin Capsules
  • Ciclosporin Oral Solution
     
  • Link  Ciclosporin Rheumatology Shared Care Guideline
     
    Tacrolimus (Adoport®, Advagraf®, Prograf®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber

    For existing patients only. Prescribe by brand name.

     
    Link  Link to Leeds Amber Drug Guidance: Tacrolimus for renal or liver transplant
     
    08.02.03  Expand sub section  Rituximab and alemtuzumab to top
    Cytotoxic Drug Obinutuzumab (Gazyvaro®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    NHS England
    BlueTeq
    • Obinutuzumab Infusion (Gazyvaro®)

    Consultant Haematologist use only

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)
    Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
    Link  NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma (March 2018)
    Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (May 2020)
     
    Cytotoxic Drug Ofatumumab  (Arzerra®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Ofatumumab Infusion (Arzerra®) 
       
     
    Link  NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)
     
    Cytotoxic Drug Rituximab (MabThera® Truxima®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    • Rituximab Infusion
    • Rituximab Subcutaneous Injection
     
    Link  NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (February 2008)
    Link  NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)
    Link  NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)
    Link  NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)
    Link  NICE TA65 Rituximab for agressive non-Hodgkins lymphoma (September 2003)
    Link  TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)
     
    08.02.04  Expand sub section  Other immunomodulating drugs
    Dimethyl fumarate (Tecfidera®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Dimethyl fumarate Capsules

      Available in line with NICE TA320 at the following specialist centres:
      Leeds Teaching Hospital Trust, Sheffield Teaching Hospital, Hull and East Yorkshire, York and Mid Yorks Trusts.
     
    Link  MHRA Drug Safety Update: Dimethyl fumarate: fatal PML in an MS patient with severe, prolonged lymphopenia (March 2015)
    Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (August 2014)
    Link  NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis (September 2017)
     
    Cytotoxic Drug Lenalidomide ( Revlimid®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    NHS England
    BlueTeq
    • Lenalidomide Capsules

    Use restricted to Consultant Haematologists only.
     
    Lenalidomide is also available for other indications via the Cancer Drugs Fund.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     

     
    Link  Cancer Drugs Fund - Lenalidomide
    Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
    Link  Drug Safety Update: Lenalidomide (Revlimid®): New important advice regarding viral reactivation (November 2016)
    Link  MHRA Drug Safety Update: Risk of thrombosis and thromboembolism (Feb 2011)
    Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (June 2009)
    Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014)
    Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
    Link  NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019)
    Link  NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019)
    Link  NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma (April 2020)
     
    Panobinostat (Farydak®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
    High Cost Medicine
    • Panobinostat Capsules


    Consultant haematologist only.

     
    Link  NICE TA380: Panobinostat for treating multiple myeloma after at least two previous treatments (January 2016)
     
    Cytotoxic Drug Pomalidomide (Imnovid®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Pomalidomide Capsules
       

    Haematology use only.

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
    Link  MHRA Drug Safety Update: Pomalidomide (Imnovid¥): risk of hepatitis B reactivation (April 2016)
    Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017)
     
    Cytotoxic Drug Thalidomide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    • Thalidomide Capsules

    Consultant Haematologist use only

     
    Link  Drug Safety Update: Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19) (May 2020)
    Link  Drug Safety Update: Thalidomide - reduced starting dose in patients older than age 75 years (December 2015)
    Link  MHRA Drug Safety Update: Thalidomide: Risk of second primary malignancies (May 2013)
    Link  MHRA Drug Safety Update: Thalidomide: risk of arterial and venous thromboembolism (July 2011)
    Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (July 2011)
     
    08.02.04  Expand sub section  Interferon Alfa
    Interferon Alfa
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Interferon Alfa-2A Injection

    Reserved for Consultant Haematologist use  
  •  
    Peginterferon Alfa
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Peginterferon Alfa-2B Prefilled Pen

    Consultant Gastroenterologist use only for the treatment of hepatitis C in combination with ribavirin capsules in line with NICE TA106, TA200 and TA75.

     
  • Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (August 2006)
    Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010)
    Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (November 2013)
     
    08.02.04  Expand sub section  Interferon beta
    08.02.04  Expand sub section  Aldesleukin
    08.02.04  Expand sub section  Glatiramer acetate to top
     note 

    Available via specialist centres only.

    08.02.04  Expand sub section  Natalizumab
    08.03  Expand sub section  Sex hormones and hormone antagonists in malignant disease
    08.03.01  Expand sub section  Oestrogens
    Diethylstilbestrol (Stilboestrol®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Green
  • Diethylstilbestrol Tablets

    For the treatment of prostate cancer under the recommendation of Consultant Oncologist. 
  •  
    Ethinylestradiol
    (Ethinyloestradiol)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Green
  • Ethinylestradiol Tablets

    For the treatment of prostate cancer under the recommendation of Consultant Oncologist. 
  •  
    08.03.02  Expand sub section  Progestogens
    Medroxyprogesterone Acetate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Red
  • Medroxyprogesterone Acetate Tablets
  • Medroxyprogesterone Acetate Injection 
  •  
    Megestrol Acetate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Green
  • Megesterol Acetate Tablets  
  •  
    08.03.03  Expand sub section  Androgens to top
    08.03.04  Expand sub section  Hormone antagonists
    08.03.04.01  Expand sub section  Breast cancer
     note 

    Adjuvant Endocrine Therapy (extended use) - GP information guide

    Anastrozole (Arimidex ®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber
  • Anastrazole Tablets

     
  • Link  NICE CG164: Familial Breast Cancer (updated March 2017)
     
    Exemestane (Aromasin®)
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber
  • Exemestane Tablets

     
  • Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
     
    Fulvestrant
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Fulvestrant Injection

    Not recommended for use. 
  • Link  NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (December 2011)
    Link  NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (January 2018)
     
    Letrozole
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber
  • Letrozole Tablets

     
  •  
    Tamoxifen
    View adult BNF View SPC online View childrens BNF  Track Changes
    Formulary
    Amber
  • Tamoxifen Tablets
  • Tamoxifen SF Solution

     
  • Link  NICE CG164: Familial Breast Cancer (updated March 2017)
     
    08.03.04.02  Expand sub section  Prostate cancer and gonadorelin analogues
    Degarelix Injection
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber
    • Degarelix Subcutaneous Injection

      Treatment is to be initiated by a Consultant Urologist and the loading dose (120mg) provided by the Trust. Subsequent maintenances doses (80mg) are to be provided by the patient’s GP.
       
     
    Link  NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer (August 2016)
     
    08.03.04.02  Expand sub section  Gonadorelin analogues
    08.03.04.02  Expand sub section  Anti-androgens to top
    Abiraterone Acetate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Abiraterone Acetate Tablets 
       
      Blueteq® registration and approval for use is required for this product before it may be dispensed.
     
    Link  EMA: Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone (March 2018)
    Link  NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (July 2016)
    Link  NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (July 2016)
     
    Bicalutamide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber
  • Bicalutamide Tablets

     
  •  
    Cyproterone Acetate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Green
  • Cyproterone Tablets

     
  • Link  Drug Safety Update: Cyproterone acetate: new advice to minimise risk of meningioma (June 2020)
     
    Enzalutamide (Xtandi® )
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
    BlueTeq
    • Enzalutamide Capsules (Xtandi®) 

    Blueteq® registration and approval for use is required for this product before it may be dispensed.

     
    Link  Cancer Drug Fund: Enzalutamide
    Link  NICE TA316: Enzalutamide for metastatic hormone-relapsed prostate cancer, previously treated with docetaxel-containing regimen (July 2014)
    Link  NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (January 2016)
    Link  TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer (May 2019)
     
    Leuprorelin Acetate
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Green
  • Leuprorelin Injection

     
  •  
    08.03.04.03  Expand sub section  Somatostatin analogues
    Lanreotide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Amber
    • Lanreotide Injection
     
     
    Octreotide
    View adult BNF View SPC online View childrens BNF  Track Changes
    Restricted Drug Restricted
    Red
  • Octreotide Injection

    1. Symptoms associated with carcinoid tumours with features of carcinoid syndrome.
    2. Prevention of complications following pancreatic surgery. 
  •  
     ....
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Green

    Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

    Amber

    Amber - these drugs require specialist initiation or recommendation  

    Amber SCG

    Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

    Red

    Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Red ULM

    Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

    Grey

    Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

    Black

    Black - Drugs not routinely commissioned so should not usually be prescribed  

    netFormulary